Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dr Axel Ullrich wins 2009 Paul Janssen Award

This article was originally published in Scrip

Executive Summary

The 2009 Dr Paul Janssen Award, worth $100,000, has been presented to Dr Axel Ullrich for pioneering the development of genomics-based therapeutics, including Genentech/Roche's HER2-targeted Herceptin (trastuzumab), which is used to treat HER2-positive breast cancer, and Pfizer's multi-targeted kinase inhibitor sunitinib malate (Sutent), which is used to treat renal cell carcinoma.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts